Ocular Therapeutix (OCUL) Accumulated Depreciation (2013 - 2025)

Ocular Therapeutix has reported Accumulated Depreciation for 13 years, with the latest figure at $27.5 million in Q4 2025.

• Accumulated Depreciation for Q4 2025 came in at $27.5 million, up 16.45% year-over-year; the trailing twelve-month figure through Dec 2025 was $27.5 million (up 16.45% YoY), and the FY2025 annual result was $27.5 million, up 16.45% from the prior year.
• Accumulated Depreciation rose to $27.5 million in Q4 2025, from $23.6 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $27.5 million in Q4 2025 and troughed at $15.2 million in Q4 2021.
• A 5-year average of $20.8 million and a median of $20.3 million in 2023 frame the typical range for Accumulated Depreciation.
• The widest annual swing landed in 2021, when Accumulated Depreciation gained 18.93%; it then rose 13.62% in 2022.
• A 5-year view of Accumulated Depreciation shows it stood at $15.2 million in 2021, then advanced by 13.62% to $17.3 million in 2022, then increased by 17.26% to $20.3 million in 2023, then increased by 16.64% to $23.6 million in 2024, then increased by 16.45% to $27.5 million in 2025.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $27.5 million in Q4 2025, $23.6 million in Q4 2024, and $20.3 million in Q4 2023.